Skip to main content

Table 1 Patient background

From: Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens

 

Total (n=60)

HLA-A24 (+) (n=35)

HLA A24 (-) (n=25)

 

Age(year)

61.8±7.6

62.3±7.1

61.1±8.2

NS

Male: Female

53/7

32/3

21/4

NS

Prior therapy

    

Operation

29(48%)

19(54%)

10(40%)

NS

Radiation

48(80%)

26(74%)

22(88%)

NS

Chemotheraphy

    

5FU

59(98%)

35(100%)

24(96%)

NS

CDDP

58(97%)

33(94%)

23(92%)

NS

Docetaxel

54(90%)

31(91%)

23(92%)

NS

  1. NS not significant between the HLA-A24(+) and HLA-A24(-) group.